Impact of CYP2E1 genotype in renal cell and urothelial cancer patients

Experimental and Toxicologic Pathology

Volumn 50, Issue 4-6, 1998, Pages 425-431

  Parker, K ^a   Lehmann, M H ^b   Oelschlagel B ^a   Haerting, J ^b   Hoffmann, A ^a   Janitzky, V ^b   Schubert, J ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cancer, renal cell; Cancer, urothelial; CYP2E1 genotype; Enzymes, genetic polymorphism; Genetic polymorphism, enzymes; Renal cell cancer; Urothelial cancer

Indexed keywords

CYTOCHROME P450; DIMETHYLNITROSAMINE DEMETHYLASE; DNA FRAGMENT;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DRUG METABOLISM; EPITHELIUM TUMOR; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; UROTHELIUM;

EID: 0031689036     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0940-2993(98)80029-8     Document Type: Article

References (26)

1. BELL DA, TAYLOR JA, PAULSON DF, et al.: Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1 ) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85 (14): 1159-1164.
2. CASCORBI I, DRAKOULIS N, BROCKMöLLER J, et al.: Arylamine N-acetyltransferase (NAT2) Mutations and Their Allelic Linkage in Unrelated Caucasian Individuals: Correlation with Phenotypic Activity. Am J Hum Genet 1995; 57:581-592.
3. BROCKMöLLER J, CASCORBI I, ROOTS I: Gene-environment synergisms in bladder cancer risk: arylamine N-acetyltransferase type 2, smoking and occupation. Int J Clin Pharmacol Ther 1996: 34 (7): 321.
4. BROCKMöLLER J, KERB R, DRAKOULIS N, et al.: Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res 1994; 54: 4103-4111.
5. CRADDOCK VM: Nitrosamines and human cancer: proof of an association. Nature 1983: 306: 638
6. DRAKOULIS N, CASCORBI I, BOCKMöLLER CR, ROOTS I: Polymorphisms in the human CYP1 Al gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region. Clin Investig 1994; 72: 240-248.
7. FARKER K, VOGT S, JANITZKY V, et al.: CYP1A1 polymorphism -no risk factor for kidney and urothelial cancer. Exp Toxic Pathol 1996; 48, Suppl. II: 113-116.
8. FARKER K, VOGT S, SCHLICHTER A, et al.: Acetylation Genotype (NAT2) in Kidney and Urothel Cancer Patients in Middle Germany. Pharmacoepidemiology and Drug Safety 1996; Vol.5, S28.
9. GUENGERICH FP: Roles of cytochrome P450 enzymes in chemical carcinogenes and cancer chemotherapy. Cancer Res 1988; 48: 2946-2954.
10. GUENGERICH FP, KIM DH, IWASAKI M: Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991 ; 4: 168-179.
11. HlRVONEN A, HUSGAFVEL-PURSIAINEN K, ANTTILA S, et al.: The human CYP2E1 gene and lung cancer: Dral and Rsal restriction fragment length polymorphism in a Finnish study. Carcinogenesis 1993; 14: 85-88.
12. HONG J, YANG CS : The nature of microsomal N-nitrosodimethylamine demethylase and its role in carcinogen activation. Carcinogens 1985; 6: 1805-1809.
13. INGELMANN-SUNDBERG M, JoHANSSON I: Mechanisms of hydroxyl radical formation of ethanol oxidation by ethanolinducible and other forms of rabbit liver microsomal cytochromes P-450. J Biol Chem 1984; 259: 6447-6458.
14. JOHANSSON I, INGELMAN-SUNDBERG M: Carbon tertrachlorideinduced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P450. FEES Lett 1985; 183: 265-269.
15. KATO S, SHIELDS PG, CAPORASO NE, et al.: Cytochrome P450IIE1 genetic polymorphisms, racial variations, and lung cancer risk. Cancer Res 1992; 52: 6712-6715.
16. MAEZAWA Y, YAMAUCHI M, TODA G: Association between restriction fragment length polymorphisms of the human cytochrome P450IIE1 gene and susceptibility to alcoholic liver cirrhosis. Am J Gastroenterol 1994; 89:561-565.
17. NAKACHI K, IMAI K, HAYASHI SI, KAWAJIRI K: Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53: 2994-2999.
18. NELSON DR, KOYMANS L, KAMATAKI T, et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
19. OYAMA T, KAWAMOTO T, MIZOUE T, et al.: Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer-Res 1997; 17(1B): 583-7.
20. O'NEiLL IK, CHEN J, BARTSCH H: Relevance to human cancer of N-nitroso compounds, tobacco and mycotoxins. Publication no. 105. Lyon, France: International Agency for Research on Cancer 1991.
21. RAUNIO H, HusGAFVEL-PuRsiAiNEN K, ANTTILA S, et al.: Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility -a review. Gene 1995; 159: 113-121.
22. SHIELDS PG, AMBROSONE CB, GRAHAM S, BOWMAN ED, et al.: A cytochrome P4502E1 genetic polymorphism and tobacco smoking in breast cancer. Mol Carcinog 1996; 17 (3): 144-50.
23. SIVARAMAN L, LEATHAM MP, YEE J, et al.: Cyp 1 Al genetic polymorphisms and in situ colorectal cancer. Cancer Res 1994; 54: 3692-3695.
24. TSUTSUMI M, MATSUDA Y, TAKADA A: Role of ethanol-inducible cytochrome P-450 2E1 in the development of hepatocellular carcinoma by the chemical carcinogen, N-nitrosodemethylamine. Hepatology 1993; 18: 1483-1489.
25. UEMATSU F, KIKUCHI H, MOTOMIYA M, et al.: Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991; 82: 254-256.
26. YANG CS, Yoo JS, ISHIZAKI H, HOXG J: Cytochrome P450IIE1: roles of nitrosamine metabolism and mechanism of regulation. Drug Metab Rev 1990; 22: 147-159.